pharmaphorum2d
End of the line for Cassava's troubled Alzheimer's programme
The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug
The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and ...
Cassava to discontinue development of Alzheimer's disease drug
(Reuters) -Cassava Sciences said on Tuesday it will discontinue the development of its experimental treatment simufilam for ...
Cassava Sciences to discontinue all efforts to develop simufilam in Alzheimer’s
We are disappointed that the results of REFOCUS-ALZ and RETHINK-ALZ showed no treatment benefit for patients with mild-to-moderate Alzheimer’s ...
BioSpace3d
Cassava Finally Ends Alzheimer’s Program for Embattled Simufilam
Cassava Sciences has officially ended development of simufilam in Alzheimer’s disease, marking the end of a tumultuous era ...
Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop
Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure treatments.
Cassava Sciences down 12% after simufilam doesn’t hit Alzheimer’s trial endpoint
Cassava shares are down 34c, or 12%, to $2.46 in pre-market trading after resuming following a halt for news pending.Light Up your Portfolio ...
MPR1d
Simufilam Fails in Second Alzheimer Disease Trial Ending Development Program
Topline results were announced from a phase 3 trial evaluating simufilam, an oral small molecule that targets the filamin A protein, for the treatment of mild to moderate Alzheimer disease (AD).